| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $132,188,755 ) (Continued on the next page) |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA265050 | New Therapuetics for Pancreatic Cancer | 000 | 1 | NIH | 5/3/2022 | $600,834 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160619 | Disrupted Sleep in Somali Americans ? Implications for Hypertension Risk | 000 | 1 | NIH | 6/9/2022 | $787,153 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG073726 | Influence of exercise training and intensity on cerebral blood flow regulation and cognitive function in mid-life adults with cardiovascular disease. | 000 | 1 | NIH | 6/9/2022 | $270,824 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03EB032958 | Development of non-contact rheometry for measuring rheological properties of biological fluids | 000 | 1 | NIH | 4/29/2022 | $79,500 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL158532 | Cellular Senescence in Neonatal Airways | 000 | 1 | NIH | 6/9/2022 | $654,905 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL158548 | Novel Therapeutics for Cardiovascular Disease | 000 | 1 | NIH | 5/12/2022 | $715,647 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076515 | Defining the interactions of senescent immune cells and skeletal cells | 000 | 1 | NIH | 5/26/2022 | $490,477 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 1 | NIH | 5/25/2022 | $325,950 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS113776 | Small Molecule Mitochondria-Targeted Therapeutics for AD | 001 | 2 | NIH | 6/16/2022 | -$778,431 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS113776 | Small Molecule Mitochondria-Targeted Therapeutics for AD | 001 | 2 | NIH | 6/16/2022 | $778,431 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS113776 | Small Molecule Mitochondria-Targeted Therapeutics for AD | 000 | 2 | NIH | 4/29/2022 | $778,431 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | T32AI170478 | Training Program in Immunology | 000 | 1 | NIH | 6/18/2022 | $158,376 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R61HL158811 | Pre-transplant health coaching to improve patient-reported outcomes in lung transplant candidates | 000 | 1 | NIH | 5/6/2022 | $484,151 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K99NS126417 | Microglial P2Y6 receptor calcium signaling as a core regulator of epileptogenesis | 000 | 1 | NIH | 5/30/2022 | $118,746 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA271410 | Mayo Clinic Center for Clinical Proteomics | 000 | 1 | NIH | 6/1/2022 | $1,140,564 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | T32GM144233 | Predoctoral Training Program in Molecular Pharmacology | 000 | 1 | NIH | 6/10/2022 | $312,217 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21HS028475 | Harnessing Health Information Technology to Promote Equitable Care for Patients with Limited English Proficiency and complex care needs | 000 | 1 | AHRQ | 4/19/2022 | $150,001 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA263003 | PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis | 000 | 1 | NIH | 1/21/2022 | $185,831 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03AG071934 | Impact of menopause associated adrenal aging on cognitive function and Alzheimer dementia neuroimaging biomarkers | 000 | 1 | NIH | 1/31/2022 | $169,178 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA271014 | Impact of Genetic susceptibility along the continuum from MGUS to MM | 000 | 1 | NIH | 4/20/2022 | $694,881 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS126227 | Seronegative Autoimmune Encephalopathies: Biomarker Discovery, Validation & Deep Phenotyping | 000 | 1 | NIH | 1/31/2022 | $364,839 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK131946 | Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia | 000 | 1 | NIH | 4/19/2022 | $315,462 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R13CA265018 | Africa Hepatopancreatobiliary Cancer Consortium | 000 | 1 | NIH | 4/14/2022 | $25,000 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DA056469 | Alaska Native Family-Based, Financial Incentives Intervention for Smoking Cessation: an RCT | 000 | 1 | NIH | 4/21/2022 | $637,627 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NR020362 | SCH: Wearable Augmented Prediction of Burnout in Nurses: A Synergy of Engineering, Bioethics, Nursing | 000 | 1 | NIH | 4/11/2022 | $149,999 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NR020362 | SCH: Wearable Augmented Prediction of Burnout in Nurses: A Synergy of Engineering, Bioethics, Nursing | 000 | 1 | NIH | 4/11/2022 | $150,000 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31AR079842 | Immunomodulation to Improve the Clinical Performance of BMP2 | 001 | 1 | NIH | 6/17/2022 | $716 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31AR079842 | Immunomodulation to Improve the Clinical Performance of BMP2 | 000 | 1 | NIH | 3/17/2022 | $46,036 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21DA055848 | Prediction and early recognition of opioid-induced respiratory depression | 000 | 1 | NIH | 3/17/2022 | $238,500 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271486 | Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis | 000 | 1 | NIH | 1/28/2022 | $506,326 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R61NS122096 | Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma. | 000 | 1 | NIH | 3/14/2022 | $397,500 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA256648 | Genetic Biomarkers for Risk of CLL Progression among high-count MBLs | 001 | 2 | NIH | 4/25/2022 | $14,911 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA256648 | Genetic Biomarkers for Risk of CLL Progression among high-count MBLs | 000 | 2 | NIH | 12/2/2021 | $167,751 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01GM144351 | Methods for microbiome compositional data | 000 | 1 | NIH | 2/28/2022 | $336,579 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK131685 | Noninvasive assessment of detrusor pressure and dysfunction | 000 | 1 | NIH | 2/10/2022 | $604,666 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK127978 | Hepatic Steatosis Quantification with Ultrasound | 000 | 1 | NIH | 3/29/2022 | $576,602 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076163 | Regulation of the lymphoid cell fate by Hoxa9 | 000 | 1 | NIH | 1/5/2022 | $318,000 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA271560 | Defining Antigen-Dependent and Antigen-Independent Mechanisms for EGFRviii-Expressing Tumor Escape From Therapy | 001 | 1 | NIH | 2/17/2022 | $0 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA271560 | Defining Antigen-Dependent and Antigen-Independent Mechanisms for EGFRviii-Expressing Tumor Escape From Therapy | 000 | 1 | NIH | 2/17/2022 | $46,036 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R35GM143949 | Fundamental and applied studies of nucleic acids | 000 | 1 | NIH | 1/27/2022 | $299,357 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG3NS123066 | Optimizing Pharmacotherapy with Noninvasive Wearable Sensors and Subscalp EEG | 000 | 1 | NIH | 2/3/2022 | $604,937 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI162678 | Context dependent amino acid availability and sensing determines humoral immunity | 000 | 1 | NIH | 2/10/2022 | $470,828 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03DK132121 | Impact of abnormal steroid metabolome on cellular senescence, frailty and cognition | 000 | 1 | NIH | 3/7/2022 | $119,250 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK130331 | Lipid metabolism and adipose tissue function | 000 | 1 | NIH | 11/25/2021 | $504,905 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA267098 | Targeting poly (ADP ribose) polymerase (PARP) in endometrial cancer | 000 | 1 | NIH | 12/1/2021 | $222,998 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 000 | 1 | NIH | 12/9/2021 | $606,332 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160761 | Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology | 000 | 1 | NIH | 12/20/2021 | $632,301 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK130884 | Pathobiology of Nonalcoholic Steatohepatitis | 000 | 2 | NIH | 6/17/2022 | $349,800 |
| | 2022 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK129241 | ADPKD: Understanding immunosuppression mechanisms and discovering treatment | 000 | 2 | NIH | 6/2/2022 | $465,096 |
|
